ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPGNext catalyst
APG2575
Chronic Lymphocytic Leukemia
Get an email about AAPG's next catalysts
Track ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 8 more upcoming events in our data (conference, Phase 3 readout, Phase 2 readout).See the timeline
9 upcoming, 0 past
Conference Presentation - APG-5918
For relapsed/refractory T-cell lymphoma. Ascentage Pharma announced that multiple studies across four drug candidates were selected for the 68th ASH Annual Meeting (Dec 12-15, 2026, New Orleans), including an oral presentation of first clinical data for APG-5918 in relapsed/refractory T-cell lymphoma. Data will also cover olverembatinib and lisaftoclax combinations in AML and pediatric Ph+ ALL.
SourceAPG2575 Phase 2 Est. Readout
Primary completion for APG2575 trial (NCT05147467) in Chronic Lymphocytic Leukemia
Sourcelisaftoclax +BTK inhibitor Phase 3 Est. Readout
Estimated primary completion for lisaftoclax +BTK inhibitor trial (NCT06104566) in CLL/SLL. Topline data typically follows completion by weeks to months.
Sourceolverembatinib Phase 2 Est. Readout
Primary completion for olverembatinib trial (NCT04501120) in Relapsed/Refractory Acute Myeloid Leukaemia
SourceOlverembatinib Phase 3 Est. Readout
Primary completion for Olverembatinib trial (NCT06640361) in GIST
SourceAPG-115 Phase 2 Est. Readout
Estimated primary completion for APG-115 trial (NCT05701306) in Neuroblastoma. Topline data typically follows completion by weeks to months.
Sourceolverembatinib Phase 3 Est. Readout
Estimated primary completion for olverembatinib trial (NCT06423911) in Chronic Myeloid Leukemia. Topline data typically follows completion by weeks to months.
Sourceolverembatinib Phase 3 Est. Readout (POLARIS-2)
Estimated primary completion for olverembatinib trial (NCT06423911) in Chronic Myeloid Leukemia. Topline data typically follows completion by weeks to months.
SourceHow AAPG's past catalysts played out
Market Overview
Stock performance and key metrics
Bosutinib
Chronic Myeloid Leukemia
APG-2575(Lisaftoclax)
Acute Myeloid Leukemia
Lisaftoclax (APG-2575)
Relapsed/Refractory Acute Myeloid Leukaemia
lisaftoclax +BTK inhibitor
CLL/SLL
BTK inhibitor
CLL/SLL
Acalabrutinib
CLL/SLL
Olverembatinib
GIST
APG2575
Chronic Lymphocytic Leukemia
Reduced-dose HHT
Relapsed/Refractory Acute Myeloid Leukaemia
standard-dose HHT
Relapsed/Refractory Acute Myeloid Leukaemia
APG-115
AML
APG-1252
NHL, Adult
Phase 1b: APG-115+pembrolizumab
Unresectable or Metastatic Melanoma or Advanced Solid Tumors
HQP1351
Chronic Myeloid Leukemia, Chronic Phase
APG-1387 for Injection
Advanced Pancreatic Cancer
APG-2575
T-Prolymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bosutinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
APG-2575(Lisaftoclax) | Phase 3 | Acute Myeloid Leukemia | - | - |
Lisaftoclax (APG-2575) | Phase 3 | Relapsed/Refractory Acute Myeloid Leukaemia | - | - |
lisaftoclax +BTK inhibitor | Phase 3 | CLL/SLL | - | - |
BTK inhibitor | Phase 3 | CLL/SLL | - | - |
Acalabrutinib | Phase 3 | CLL/SLL | - | - |
Olverembatinib | Phase 3 | GIST | - | - |
APG2575 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Reduced-dose HHT | Phase 2 | Relapsed/Refractory Acute Myeloid Leukaemia | - | - |
standard-dose HHT | Phase 2 | Relapsed/Refractory Acute Myeloid Leukaemia | - | - |
APG-115 | Phase 2 | AML | - | - |
APG-1252 | Phase 2 | NHL, Adult | - | - |
Phase 1b: APG-115+pembrolizumab | Phase 2 | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | - | - |
HQP1351 | Phase 2 | Chronic Myeloid Leukemia, Chronic Phase | - | - |
APG-1387 for Injection | Phase 2 | Advanced Pancreatic Cancer | - | - |
APG-2575 | Phase 2 | T-Prolymphocytic Leukemia | - | - |
Frequently asked questions
What is in ASCENTAGE PHARMA GROUP INTERNATIONAL's drug pipeline?→
CatalystAlert tracks 16 drug candidates in ASCENTAGE PHARMA GROUP INTERNATIONAL's (AAPG) pipeline across Phase 3, Phase 2. Its lead program is Olverembatinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ASCENTAGE PHARMA GROUP INTERNATIONAL's next FDA catalyst?→
ASCENTAGE PHARMA GROUP INTERNATIONAL's (AAPG) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AAPG biotech catalysts?→
Add AAPG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ASCENTAGE PHARMA GROUP INTERNATIONAL's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.